Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 3/20 | 0.71 |
| ▸ | CLK1 | P49759 | 1/20 | 0.71 |
| ▸ | PRKCI | P41743 | 1/20 | 0.58 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | OGA | O60502 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.52 |
| ▸ | CASP7 | P55210 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29660339 | 0.82 | RAB9A (0.53) | RAB9ANPC1CLK1PRKCIPRKCZ | |
| SCHEMBL21523865 | 0.80 | NPC1 (0.67) | RAB9ANPC1KDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL27108838 | 0.79 | RAB9A (0.72) | RAB9ANPC1CLK1GAASMN1; SMN2 | |
| SCHEMBL12582252 | 0.79 | RAB9A (0.72) | RAB9ANPC1CLK1GAASMN1; SMN2 | |
| SCHEMBL18002724 | 0.78 | RAB9A (0.61) | RAB9ANPC1CLK1GAAKDM4E | |
| SCHEMBL17055675 | 0.78 | HSD17B10 (0.57) | RAB9ANPC1PRKCIPRKCZGAA | |
| SCHEMBL6243166 | 0.77 | CDK5 (0.70) | RAB9ANPC1CLK1PRKCIPRKCZ | |
| SCHEMBL28154886 | 0.77 | RAB9A (0.70) | RAB9ANPC1CLK1GAASMN1; SMN2 | |
| SCHEMBL9911662 | 0.77 | RAB9A (0.60) | RAB9ANPC1CLK1GAASMN1; SMN2 | |
| SCHEMBL18573584 | 0.77 | CDC7 (0.60) | RAB9ANPC1PRKCIPRKCZKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1073428-B1 | DIHYDROXYPHENYL DERIVATIVES FOR HEPATOPROTECTION AND TREATMENT OF LIVER DISEASES | CHOONGWAE PHARMA CO LTD (KR) | 2004-10-27 | — | — | EP | disclosed |
| US-6693126-B2 | OXIME-SUBSTITUTED M-DIHYDROXYBENZENE OR 1,3-BENZODIOXOLE COMPOUND OF GIVEN FORMULA AND AN INERT CARRIER | CHOONGWAE PHARM. CO., LTD. (KR) | 2004-02-17 | — | — | US | disclosed |
| US-20030083326-A1 | Dihydroxyphenyl derivatives for hepatoprotection and treatment of liver diseases | CHOONGWAE PHARM. CO., LTD. (KR) | 2003-05-01 | — | — | US | disclosed |
| EP-1073428-A1 | DIHYDROXYPHENYL DERIVATIVES FOR HEPATOPROTECTION AND TREATMENT OF LIVER DISEASES | Choongwae Pharma Co., Ltd. (KR) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055318-A1 | DIHYDROXYPHENYL DERIVATIVES FOR HEPATOPROTECTION AND TREATMENT OF LIVER DISEASES | CHOONGWAE PHARM. CO., LTD. (KR) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083326-A1 | Dihydroxyphenyl derivatives for hepatoprotection and treatment of liver diseases | SLC10A1, SLC10A2, ABCB11 | RAB9A 1669/4885NPC1 99/4885CLK1 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.